Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma
- 17 August 2010
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Oncology
- Vol. 22 (3), 718-722
- https://doi.org/10.1093/annonc/mdq425
Abstract
Background: To evaluate the efficacy and toxicity of single-agent docetaxel (Taxotere) as therapy in patients with disseminated nasopharyngeal carcinoma (NPC). Patients and methods: Patients with histologically confirmed metastatic or recurrent NPC who have failed at least one line of palliative chemotherapy regimen but no prior docetaxel were eligible. Patients received weekly docetaxel every 28 days (docetaxel 30 mg/m2 on days 1, 8 and 15) and were evaluated every two cycles of treatment of response assessment. Quality-of-life (QoL) assessments during the treatment period were done using the European Organization for Research and Treatment of Cancer QoL questionnaire QLQ-C30; version 3.0. Results: Thirty patients were assessable for toxicity and response. The median age of the patients was 47 years (range 25–68 years) and the majority of patients had good performance status (Eastern Cooperative Oncology Group 0–1). Grade 3 or 4 toxicity included fatigue (13%), anemia (10%) and diarrhea (3%) of patients. Eleven (37%) and four (13.3%) patients achieved partial response and stable disease, respectively. The median progression-free survival was 5.3 months and median overall survival of 12.8 months. The partial responders had a mean duration of response of 4.1 months. Docetaxel caused a significant decline in QoL scores during treatment of patients responding or progressing with the treatment. Conclusions: Our findings suggest that weekly docetaxel is well tolerated and is an active agent in patients with disseminated NPC who were previously exposed and largely refractory to platinum-based chemotherapy but can cause a significant decline in QoL during treatment.Keywords
This publication has 16 references indexed in Scilit:
- Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancerCancer, 2008
- A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based ChemotherapySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialAnnals of Oncology, 2005
- Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic VarietyJournal of Clinical Oncology, 2005
- Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinomaCancer, 2005
- Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)Annals of Oncology, 2005
- Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated typeAnnals of Oncology, 2002
- Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinomaAnnals Of Oncology, 1999
- Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancerAnnals of Oncology, 1998